GLP-1 agonists — mechanism and outcomes
How semaglutide and tirzepatide combine A1c reduction with weight loss and cardiovascular protection. Where the class fits in Indian clinical practice today.
GLP-1 receptor agonists have become the most talked-about diabetes class of the last decade.
Mechanism
They mimic GLP-1, an incretin hormone released by the gut after eating. Effects: increase insulin secretion only when blood sugar is high (no hypo unless combined with insulin/sulfonylurea), slow stomach emptying (early satiety), reduce appetite (central effect), modest beta-cell preservation.
Outcomes
Semaglutide and tirzepatide show A1c reductions of 1.5-2.0 percentage points, weight loss of 10-20%, and cardiovascular event reduction in dedicated trials.
Indian context
Cost remains the limiting factor. Once-weekly injectables run higher than oral metformin. Newer oral formulations may shift access over time. Always a doctor's decision.